National Center for Tumor Diseases / German Cancer Consortium (NCT/DKTK) Molecularly Aided Stratification for Tumor Eradication Research (MASTER)
NCT MASTER Program
","eudractNumber":null,"id":4421,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2018-01-01T11:14:24+01:00","shortTitle":"NCT-Studie: MASTER Programm","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Prospektive Beobachtungsstudie mit Erstellung einer Biodatenbank zur Untersuchung potentieller Biomarker für Risikostratifizierung, Therapiesteuerung und Verträglichkeit in Patient*innen mit neuroendokrinen Neoplasien (NENReg)","eudractNumber":null,"id":11499,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-11-01T09:14:44+01:00","shortTitle":"NENReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Multizentrische, länderübergreifende, prospektive, beobachtende Unbedenklichkeitsstudie zur Beschreibung der Inzidenz der Abbruchquote aufgrund von Diarrhoe innerhalb der ersten 3 Monate der Behandlung mit Neratinib bei erwachsenen Brustkrebspatienten als erweiterte adjuvante Behandlung in einem realen Umfeld: die NERLYFE-Studie","eudractNumber":null,"id":9352,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-10T10:14:43+02:00","shortTitle":"NERLYFE-Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Registry of the NHL-BFM study group for all subtypes of\nNon-Hodgkin lymphoma diagnosed in\nchildren and adolescents Gesellschaft für Pädiatrische\nOnkologie und Hämatologie (GPOH)
","eudractNumber":null,"id":11279,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2025-02-24T11:39:54+01:00","shortTitle":"NHL-BFM Registry V.2024.1","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial","eudractNumber":"2018-005027-16","id":6809,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"}],"mutations":[{"name":"1p/19q-Kodeletion","id":"mt_261"}],"nctNumber":"NCT05331521","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-06-17T09:38:59+02:00","shortTitle":"NOA-18 / IMPROVE CODEL: the NOA-18 trial","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Multizentrisches Register zur Erfassung des Nasopharynxkarzinoms bei Kindern, Jugendlichen und jungen Erwachsenen","eudractNumber":null,"id":6810,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2017-08-24T13:41:02+02:00","shortTitle":"NPC-2016 Registry","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Nivolumab in combination with cisplatin and 5-flurouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma","eudractNumber":"2021-006477-32","id":7476,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT06019130","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-05-17T11:59:46+02:00","shortTitle":"NPC-Nivo","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"Dieses Single Patient\nRequest (SPR) / Named Patient Program (NPP) / Intermediate Expanded Access\nProgram (I-EAP) soll einen frühzeitigen Zugang zu\nNiraparib/Abirateronacetat-Kombination (JNJ- 67652000) zur Anwendung mit\nPrednison oder Prednisolon vor der Zulassung ermöglichen, um einen kritischen\nungedeckten Bedarf bei Patienten mit Prostatakrebs zu decken, die ein\nmetastasiertes kastrationsresistentes Prostatakarzinom (mCRPC) entwickelt haben\nund bei denen homologe Rekombinationsreparatur (HRR)-Genveränderungen (Keimbahn\nund/oder somatisch) positiv sind.","eudractNumber":null,"id":7946,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-14T16:19:57+02:00","shortTitle":"NPP 67652000MPC4001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]}]}